Move Over Botox: There’s A New Tox In Town

The aesthetics industry is buzzing with the news that they’re soon going to be able to get their medical gloves on a brand spanking new botulinum toxin. You know, that favourite neuromodulator of yours, the one that makes those upper face lines vanish? It’s been a long time since there’s been any real advancements in these toxins, so this is big news!

Alluzience® is Europe’s first ready-to-go treatment for moderate to severe Glabellar (frown) lines that lasts up to SIX MONTHS, it’s from Galderma who is presenting all the facts and figures at the 2022 AMWC and aesthetics practitioners are chomping at the bit to try it!

What’s So Good About It?

Essentially, and the bit your patients will love, is that it appears to work sooner and last longer!

Add to this, that all currently approved BoNT-A products (or formulations) in Europe come in powder form and require reconstitution, Alluzience is a ready-to-use liquid formulation! Thus avoiding any calculations which allows for more precision and the potential to improve safety and dosing accuracy compared with the powder form.

But the big news is that Gladerma has said it lasts up to six months, which obviously your patients will be cock-a-hoop for. Who knows, this could be a really interesting revenue stream for you? Charge more for longer-lasting treatments? See patients less but achieve the same results? Win, win.

Patients Like It!

To get it ready for market, data was pooled from two pivotal trials of 372 patients with moderate to severe glabellar lines who were treated with either Alluzience®  or placebo.

It demonstrated that more than 50% of patients reported an effect within two to three days, including 23% of patients within one day and the effect was demonstrated for up to six months after injection with Alluzience®

85.2% of the patients receiving Alluzience® were either satisfied or very satisfied compared to 9% for placebo patients.

Any Bad News?

Not really, the majority of adverse reactions reported with Alluzience® in clinical trials were of mild to moderate intensity and reversible. The most frequently reported adverse reactions were headache and injection site reactions.

GlowdayPRO will certainly keep you updated on how our practitioners get on with this new product! Keep your eyes peeled on our Instagram feed

For more information on how GlowdayPRO can help you manage your time, patients and marketing needs, head here.